BACKGROUND NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to receive a 72-hour infusion of placebo or intravenous...

BACKGROUND AND PURPOSE NXY-059 has substantial protective effects when administered immediately after the onset of ischemia in a primate model of stroke. This study examined the efficacy of this drug when administered 4 hours after onset, a more clinically relevant time point. METHODS Before surgery, marmosets were trained and tested on a number of neurological tests, which assessed general n...

Pigeons are known to be able to categorize a wide variety of visual stimulus classes. However, it remains unclear which are the characteristics of the perceptually relevant features employed to reach such good performance. Here, we investigate the relative contributions of texture and shape information to categorization decisions about complex natural classes. We trained three groups of pigeons...

BACKGROUND AND PURPOSE In animal models of acute ischemic stroke (AIS), the free radical-trapping agent NXY-059 showed promise as a neuroprotectant. SAINT I and II were randomized, placebo-controlled, double-blind trials to investigate the efficacy of NXY-059 in patients with AIS. METHODS Patients with AIS received an infusion of intravenous NXY-059 or placebo within 6 hours from the onset of...

The free radical trapping agents NXY-059 and alpha-phenyl-N-tert.-butylnitrone (PBN) markedly reduce infarct volume, even when given 1 or 3 h after the start of recirculation, following 2 h of middle cerebral artery (MCA) occlusion in rats. Their anti-ischemic effects are shared by the two immunosuppressants cyclosporin A (CsA) and FK506. Interestingly, CsA causes an additional reduction in inf...

The SAINT I trial published in the February 9, 2006 issue of the New England Journal of Medicine represents the first “positive” neuroprotective trial in stroke.1 This breaks a long string of “neuroprotective” failures and indicates some hope for stroke treatment.2 Is NXY-059 a better drug than previous failed agents or was the trial just better designed? Probably both. NXY-059 is the first age...

The performance and reliability implications of DC-to-RF dispersion effects are addressed. The proposed physical explanations and technological counteractions are reviewed. GaAsand GaN-based FET technologies are considered, trying to point out both similar and peculiar aspects. * Corresponding author. [email protected] Tel: +39 059 205 6160; Fax: +39 059 205 6160.

The SAINT I trial published in the February 9, 2006 issue of the New England Journal of Medicine represents the first “positive” neuroprotective trial in stroke.1 This breaks a long string of “neuroprotective” failures and indicates some hope for stroke treatment.2 Is NXY-059 a better drug than previous failed agents or was the trial just better designed? Probably both. NXY-059 is the first age...

Correspondence: Giuseppe Longo, Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Sezione di Medicina Interna, via Del Pozzo 71, 41100 Modena, Italy. Phone: international +39-059-422782 – Fax: international +39-059-424549 – E-mail: [email protected] aware that some thrombocytopenias of uncertain etiology may be artifactual in particular conditions; spurious thrombocytopenia due to EDTA-...